- Previous Close
2.8700 - Open
2.7900 - Bid 2.7200 x --
- Ask 2.8900 x --
- Day's Range
2.7700 - 2.8200 - 52 Week Range
2.1100 - 3.1200 - Volume
8,813 - Avg. Volume
4,009 - Market Cap (intraday)
130.96M - Beta (5Y Monthly) 1.46
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4100 - Earnings Date Apr 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.70
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors. It is also developing TLX250-CDx, a diagnostic antibody for diagnosing renal cancer that is in Phase III trials; and triple-negative breast cancer. In addition, the company develops TLX250 (girentuximab), a diagnostic antibody, which is in Phase II study for patients with advanced clear cell renal cell carcinoma; RHB-107, an oral serine protease inhibitor that is in Phase II study to treat COVID-19. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.
heidelberg-pharma.comRecent News: HPHA.DE
View MorePerformance Overview: HPHA.DE
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HPHA.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HPHA.DE
View MoreValuation Measures
Market Cap
130.96M
Enterprise Value
94.55M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
15.46
Price/Book (mrq)
3.66
Enterprise Value/Revenue
11.16
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-282.98%
Return on Assets (ttm)
-20.82%
Return on Equity (ttm)
-48.33%
Revenue (ttm)
6.85M
Net Income Avi to Common (ttm)
-19.38M
Diluted EPS (ttm)
-0.4100
Balance Sheet and Cash Flow
Total Cash (mrq)
29.42M
Total Debt/Equity (mrq)
0.53%
Levered Free Cash Flow (ttm)
-23.51M